Although we can’t organically become the next Sun Pharma in five years’ time, we can definitely surpass Cipla or Abbott,” avers Mankind director Arjun Juneja when asked how his company will get to the next level without making any notable acquisitions. Several of the country’s pharma players have taken the inorganic route to fuel growth, but Mankind stands out as a rebel that has bucked this trend. Painstakingly built by Arjun’s father RC Juneja in the dusty hinterland of north India, Mankind has been acknowledged as a success story that used the bottom-up strategy to its advantage. According to a November 2015 research report, the 20-year-old company is in fourth spot in the market, after Sun, Abbott and Cipla (in that order) in terms of both sales and market share. This ranking was certainly playing on Arjun’s mind when he made his statement about Mankind’s future. But after a realistic rethink, he offers a relatively more staid claim, focusing instead on the difference between Mankind and the 80-year-old Cipla. “The company has a 5.5% market share, while ours is 4%. We should be able to cover that gap in two years.” While we will deal with this 1.5% deficit later in the story, the point to ponder here would be: what gives the company the confidence to make such claims?
One giant leap for Mankind
Mankind Pharma made it big in small towns, but can its magic help it conquer the bigger markets?
Summer wine and salad
Kishore Singh - January 19, 2015
The million-dollar question: Is investing a game of luck or skill?
Shankar Sharma - May 04, 2021
Every crisis is an opportunity, if you are on the right side of equities
Samir Arora - May 04, 2021
Viraj Mehta trusts the toughness and bounce of a company that has seen many trials
Viraj Mehta - May 04, 2021
Safir Anand spots a mid-sized company with the right chemistry and catalytic circumstances
Safir Anand - May 07, 2021